Beyond Air (XAIR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Oct, 2026Executive summary
Annual meeting scheduled for Dec. 10, 2026; proposals cover five director seats, auditor ratification, advisory executive-pay approval and possible adjournment to solicit votes.
Fiscal year-end changed from March 31 to Dec. 31, creating a transition period from April 1 through Dec. 31, 2026; the next fiscal year begins Jan. 1, 2027.
Voting matters and shareholder proposals
Board recommends FOR all five director nominees and FOR auditor ratification, say-on-pay and adjournment if needed.
Director election requires a plurality; auditor, say-on-pay and adjournment proposals each require a majority of shares present or represented and entitled to vote.
Stockholders of record as of Oct. 12, 2026 may vote; 1,665,482 common shares were outstanding, with one vote per share and no cumulative voting.
Bylaw nominations and proposals for the next annual meeting generally must arrive Aug. 12–Sept. 11, 2027; Rule 14a-19 notice for opposition director nominees is due by Oct. 11, 2027.
Board of directors and corporate governance
Five directors are nominated; four are independent under Nasdaq standards. Robert F. Carey is board chair and Robert S. Goodman is CEO.
Board held seven meetings in FY ended March 31, 2026; each director attended at least 75% of applicable board and committee meetings.
Audit, compensation and nominating committees met five, two and two times, respectively, in FY ended March 31, 2026.
Board will continue reassessing its leadership structure; stockholders may send communications to the board through the CEO, with the Corporate Secretary forwarding appropriate matters.
Latest events from Beyond Air
- Tankless nitric oxide therapy platform drives rapid growth and global market expansion.XAIR
Corporate presentation - Generation 2 device approval is set to unlock a $400M+ market with immediate deployment planned.XAIR
12th Annual Cantor Fitzgerald Global Healthcare Conference - Up to 5.4M shares registered for resale after a $10.2M private placement; focus on LungFit® growth.XAIR
Registration filing - Flat revenue, improved margins, and strong outlook depend on FDA approval and new product launch.XAIR
Q1 2027 - Revenue up 107% to $7.7M; Gen 2 launch and approval expected to drive major growth in 2027.XAIR
Q4 2026 - Shareholders will vote on a reverse stock split to maintain Nasdaq listing and avoid delisting risks.XAIR
Proxy filing - Vote on a reverse stock split to maintain Nasdaq listing and authorize meeting adjournment if needed.XAIR
Proxy filing - Q3 revenue up 105% YoY, net loss narrowed, and global expansion continues.XAIR
Q3 2026 - Next-generation system and global partnerships position the company for accelerated growth by 2027.XAIR
Piper Sandler 36th Annual Healthcare Conference